Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial
2010
AbstractObjective:Painful diabetic peripheral neuropathy (DPN) may not be adequately managed with available therapeutic options. This phase III, randomized-withdrawal, placebo-controlled trial evaluated the safety and efficacy of tapentadol extended release (ER) for relieving painful DPN.Research design and methods:Patients (n = 588) with at least a 3-month history of opioid and/or non-opioid analgesic use for DPN, dissatisfaction with current treatment, and an average pain intensity score of at least 5 on an 11-point numerical rating scale (NRS; 0 = ‘no pain,’ 10 = ‘pain as bad as you can imagine’) were titrated to an optimal dose of tapentadol ER (100–250 mg bid) during a 3-week open-label phase. Subsequently, patients (n = 395) with at least a 1-point reduction in pain intensity were randomized 1:1 to receive placebo or the optimal fixed dose of tapentadol ER determined during the open-label phase for a 12-week double-blind phase.Clinical trial registration: NCT00455520.Main outcome measures:The primar...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
51
References
205
Citations
NaN
KQI